CEBP  Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, F. P.
Right arrow Articles by Whittemore, A. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, F. P.
Right arrow Articles by Whittemore, A. S.
Cancer Epidemiology Biomarkers & Prevention Vol. 8, 649-658, August 1999
© 1999 American Association for Cancer Research


The Eighth AACR American Cancer Society Award Lecture on Cancer Epidemiology and Prevention

Genetically Tailored Preventive Strategies: an Effective Plan for the Twenty-first Century?1

Frederick P. Li and Alice S. Whittemore2

Stanford University School of Medicine, Stanford, California 94305 [AW]

Abstract

A preventive strategy of considerable appeal would offer specific lifestyle changes and preventive interventions to people at increased cancer risk because of inherited susceptibility. The hope for such a strategy stems in part from the variation in risk among carriers of cancer-predisposing mutations. For example, despite the high risks of cancers of the breast and ovary among BRCA1 and BRCA2 mutation carriers, some 30% of these women are estimated to reach age 70 years without developing either cancer. We need to know what protects these women, compared with carriers who do develop these malignancies. Apart from chance, possible explanations include variation in type of mutation, in genotypes at other loci, or in potentially modifiable lifestyle characteristics. This article reviews our present knowledge about risks for cancers of the colorectum, female breast, and ovary in carriers of highly penetrant germ-line mutations of susceptibility genes. The paper also reviews our present knowledge about options for reducing these risks through changes in lifestyle, chemopreventive agents, and prophylactic surgery. It concludes with a discussion of what we need to know to offer those with inherited susceptibility safe, effective options for preventing these cancers and to provide a framework for deciding among the options.




This article has been cited by other articles:


Home page
JCOHome page
L. S. Acheson, S. J. Zyzanski, K. C. Stange, A. Deptowicz, and G. L. Wiesner
Validation of a Self-Administered, Computerized Tool for Collecting and Displaying the Family History of Cancer
J. Clin. Oncol., December 1, 2006; 24(34): 5395 - 5402.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
L. Wideroff, A. N. Freedman, L. Olson, C. N. Klabunde, W. Davis, K. P. Srinath, R. T. Croyle, and R. Ballard-Barbash
Physician Use of Genetic Testing for Cancer Susceptibility: Results of a National Survey
Cancer Epidemiol. Biomarkers Prev., April 1, 2003; 12(4): 295 - 303.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 1999 by the American Association for Cancer Research.